Completed PHASE4 INTERVENTIONAL 2-arm NCT01505673

Adding Liraglutide to High Dose Insulin: Breaking the Cycle

Sponsor: Ildiko Lingvay

Conditions Obesity Type 2 Diabetes Mellitus

Updated 9 times since 2017 Last updated: Dec 15, 2017 Started: Jan 31, 2012 Primary completion: Jun 30, 2016 Completion: Jun 30, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Obesity and Type 2 Diabetes Mellitus and is currently completed. Ildiko Lingvay leads this study, which shows 9 recorded versions since 2012 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2023 — Jul 2024 [monthly]

Completed PHASE4
Dec 2022 — Jan 2023 [monthly]

Completed PHASE4
Jan 2021 — Dec 2022 [monthly]

Completed PHASE4

▶ Show 4 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Dec 2017 — Jun 2018 [monthly]

Completed PHASE4
Feb 2017 — Dec 2017 [monthly]

Completed PHASE4
Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

Jan 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ildiko Lingvay
Novo Nordisk A/S

Data source: University of Texas Southwestern Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Dallas, United States